title: AIDS retrovirus antibodies in hemophiliacs treated with factor VIII or factor IX concentrates, cryoprecipitate, or fresh frozen plasma: prevalence, seroconversion rate, and clinical correlations.
abstract: Antibodies to the AIDS retrovirus, specifically to human T cell lymphotropic virus, type III, and AIDS-associated retrovirus, were detected with increasing prevalence in a population of 190 hemophiliacs from western Pennsylvania between 1981 and 1984: 7.7% in 1981, 20.0% in 1982, 45.5% in 1983, and 62.5% in 1984. The seropositive included approximately three fourths of those receiving factor VIII concentrate, nearly one third of those receiving factor IX concentrate, nearly one fifth of those receiving cryoprecipitate, and none of those receiving fresh frozen plasma. The seroconversion rate, determined on 43 seropositive hemophiliacs from this group who were serially sampled, was 0% in 1977, 4.7% in 1978, 4.9% in 1979, 2.6% in 1980, 10.5% in 1981, 52.9% in 1982, 87.5% in 1983, and 100% in 1984. Of 27 seropositive for three or more years (since 1982 or before), four (15%) have developed AIDS and seven (26%), diffuse lymphadenopathy (ARC); of 16 seropositive for less than three years, none has developed AIDS and three (19%) have developed ARC. The mean time from seroconversion to onset of ARC, 0.8 +/- 0.2 years (SEM), was shorter (P less than .001) than the time to onset of AIDS, 4.1 +/- 0.6 years. These findings confirm the widespread presence of AIDS retrovirus and support the association of these retroviruses with the acquired immunodeficiency syndrome and related conditions.
authors.forename: M V
authors.initials: MV
authors.lastname: Ragni
authors.forename: G E
authors.initials: GE
authors.lastname: Tegtmeier
authors.forename: J A
authors.initials: JA
authors.lastname: Levy
authors.forename: L S
authors.initials: LS
authors.lastname: Kaminsky
authors.forename: J H
authors.initials: JH
authors.lastname: Lewis
authors.forename: J A
authors.initials: JA
authors.lastname: Spero
authors.forename: F A
authors.initials: FA
authors.lastname: Bontempo
authors.forename: C
authors.initials: C
authors.lastname: Handwerk-Leber
authors.forename: W L
authors.initials: WL
authors.lastname: Bayer
authors.forename: D H
authors.initials: DH
authors.lastname: Zimmerman
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000209:etiology; D000914:Antibodies, Viral / Q000032:analysis*; D005164:Factor IX / Q000627:therapeutic use*; D005169:Factor VIII / Q000627:therapeutic use*; D005340:Fibrinogen / Q000627:therapeutic use*; D006678:HIV / Q000276:immunology*; D015483:HIV Antibodies; D006467:Hemophilia A / Q000382:microbiology* / Q000628:therapy; D006801:Humans; D010949:Plasma; D013997:Time Factors
chemical_list: D000914:Antibodies, Viral; D015483:HIV Antibodies; C026912:cryoprecipitate coagulum; D005169:Factor VIII; D005164:Factor IX; D005340:Fibrinogen